Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
39.16
-0.57 (-1.43%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,573,210
Open
39.42
Bid (Size)
39.11 (100)
Ask (Size)
39.48 (100)
Prev. Close
39.73
Today's Range
38.82 - 39.65
52wk Range
24.05 - 41.24
Shares Outstanding
388,132,400
Dividend Yield
2.25%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?
November 12, 2025
Royalty Pharma trades at $39.59 and has moved in lockstep with the market. Its shares have returned 20.6% over the last six months while the S&P 500 has gained 16.4%.
Via
StockStory
Topics
Stocks
Supply Chain
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
November 06, 2025
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....
Via
MarketMinute
Topics
Intellectual Property
Performance
YTD
+51.8%
+51.8%
1 Month
+7.8%
+7.8%
3 Month
+9.0%
+9.0%
6 Month
+14.3%
+14.3%
1 Year
+52.4%
+52.4%
More News
Read More
Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance
↗
November 05, 2025
Via
Chartmill
Topics
Earnings
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
How Do Investors Really Feel About Royalty Pharma?
↗
September 16, 2025
Via
Benzinga
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?
↗
November 05, 2025
Via
Benzinga
Topics
Economy
Royalty Pharma Reports Third Quarter 2025 Results
November 05, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
November 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
November 03, 2025
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings
November 03, 2025
Via
StockStory
Topics
Artificial Intelligence
ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup
↗
November 01, 2025
Via
Chartmill
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
↗
October 31, 2025
Via
MarketBeat
2 Reasons to Avoid RPRX and 1 Stock to Buy Instead
October 29, 2025
Via
StockStory
Topics
Government
Stocks
Supply Chain
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data
↗
October 28, 2025
Via
MarketBeat
Royalty Pharma Declares Fourth Quarter 2025 Dividend
October 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
3 Healthcare Stocks We Keep Off Our Radar
October 13, 2025
Via
StockStory
Topics
Economy
Stocks
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 09, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
September 29, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
September 19, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
September 17, 2025
Via
StockStory
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
September 11, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
September 10, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges
September 08, 2025
Via
StockStory
Topics
Economy
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Frequently Asked Questions
Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 39.16
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 11/14/25 04:00 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 15.20B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 15B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.